SCHEDULE: Armistice Capital Discloses 9.99% Stake in CNS Pharma

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in CNS Pharmaceuticals Inc. common stock.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 561,148 shares of CNS Pharmaceuticals Inc. common stock.
• This ownership represents 9.99% of the company's common stock outstanding.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• Both reporting persons share voting and dispositive power over all 561,148 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of beneficial ownership and does not contain performance metrics or forward-looking statements.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional stake provides transparency regarding the ownership structure and may influence investor perception.

Key Dates

Keywords

CNS Pharmaceuticals, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Stock, Investment Management, Institutional Investor, Pharmaceuticals